Position in MYGN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$227,469
+$22,323 QoQ
Shares Held
39,837
+3.1% QoQ
Ownership
0.042%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#95
of 196 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $4,328,155 across 10 Diagnostics & Research names. MYGN ranks #9 (5.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NTRA |
Natera, Inc.
|
2,582 | $700,883 | |
| 2 | LH |
Labcorp Holdings Inc.
|
2,321 | $649,880 | |
| 3 | FLGT |
Fulgent Genetics, Inc.
|
27,999 | $574,539 | |
| 4 | MEDP |
Medpace Holdings, Inc.
|
1,036 | $548,655 | |
| 5 | A |
Agilent Technologies, Inc.
|
3,150 | $418,414 | |
| 6 | NEO |
Neogenomics Inc
|
23,869 | $348,248 | |
| 7 | IDXX |
Idexx Laboratories Inc /De
|
635 | $334,289 | |
| 8 | GH |
Guardant Health, Inc.
|
2,083 | $312,512 |
All Filings in MYGN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $227,469 | 39,837 | Shares | Sole | 2026-08-13 | |
| 2025-06-30 | $205,146 | 38,634 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $267,465 | 30,154 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $683,937 | 49,886 | Shares | Sole | 2025-02-11 | |
| 2023-12-31 | $53,955 | 2,819 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||